Clinical Trials Sponsored by Cerecor Inc

Total 35523 results

CeleCor Therapeutics

Recruiting

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI (CELEBRATE)

ST-elevation Myocardial Infarction (STEMI)

Netherlands, Canada, Czechia, France, Hungary, Romania
ReCor Medical, Inc.

Recruiting

The "Global Paradise System" Registry (GPS Registry)

Hypertension

Germany, Netherlands, Belgium, France, Monaco, Switzerland, United Kingdom
ReCor Medical, Inc.

Completed

REnAL denervatIon by ultraSound Transcatheter Emission (REALISE)

Resistant Hypertension

France
ReCor Medical, Inc.

Active, not recruiting

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension (RADIANCE-II)

Cardiovascular Diseases | Vascular Diseases | Hypertension

United States, United Kingdom, Netherlands, France, Ireland, Belgium, Germany, Switzerland
ReCor Medical, Inc.

Active, not recruiting

A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN)

Vascular Diseases | Hypertension

United States, Netherlands, United Kingdom, Germany, France, Poland, Belgium
ReCor Medical, Inc.

Completed

TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE) (ACHIEVE)

Resistant Hypertension

Germany, Sweden, Netherlands
ReCor Medical, Inc.

Not yet recruiting

Global Paradise System US Post Approval Study (US GPS)

Cardiovascular Diseases | Vascular Diseases | Hypertension
ReCor Medical, Inc.

Active, not recruiting

RADIANCE Continued Access Protocol (RADIANCE CAP)

Cardiovascular Diseases | Vascular Diseases | Hypertension | Hypertension, Resistant to Conventional Therapy

United States
Cerecin

Completed

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

Alzheimer Disease

United States
Cerecin

Terminated

Tricaprilin Liquid Formulation PK Study

Alzheimer Disease

Australia
Cerecin

Withdrawn

A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

Alzheimer's Disease
Cerecin

Completed

Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly

Alzheimer's Disease

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

Attention Deficit Hyperactivity Disorder

United States
Cerecin

Completed

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

Alzheimer Disease

United States
Cerecin

Completed

Taste-masking Study for Tricaprilin in Sensory Panelists (TMS)

Taste Profile Assessments

United States
Cerecin

Completed

Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production

Alzheimer Disease

Australia
Cerecin

Withdrawn

Medical Food Formulation Pharmacokinetic (PK) Study in Medium Chain Triglycerides

Alzheimer Disease
Cerecin

Withdrawn

AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) (ALERT)

Alzheimer's Disease

United States
Cerecin

Not yet recruiting

Tricaprilin Phase 3 AD Study

Alzheimer Disease
Cerecin

Completed

Tricaprilin Phase 2 Pilot Study in Migraine

Migraine

Australia
Cerecin

Completed

AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions

Alzheimer Disease

Australia
Cerecin

Active, not recruiting

Tricaprilin Infantile Spasms Pilot Study

Infantile Spasm

Singapore, Australia
Cerecare

Completed

Impact Study on Cerecare Compression Garments in the Treatment of Ehlers-Danlos Syndromes

Eds, Unspecified Type

France
Cerecin

Completed

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH-AD)

Alzheimer's Disease

United States
Rexecor

Unknown

Registry on the EXperience of Extracorporeal CO2 Removal in Intensive Care Units (REXECOR)

Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease | Patients With Acute Respiratory Distress Syndrome

France
Cerecin

Completed

Tricaprilin in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Cerecin

Completed

Tricaprilin In Age-Associated Memory Impairment

Age-Associated Memory Impairment

United States
Cerecin

Completed

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

Alzheimer Disease

Australia
Cerecin

Completed

Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease (ACT)

Alzheimer's Disease
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

22q11.2 Deletion Syndrome

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Acute Lung Injury | ARDS | COVID-19 Pneumonia

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Cerecin
Celerion

Completed

Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

Healthy

United States
Cerecin
Celerion

Completed

Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production

Healthy

United States
Cerecin
Celerion

Completed

Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production

Healthy

United States
Cerecin
Celerion

Completed

Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production

Healthy

United States
Erasmus Medical Center
ReCor Medical, Inc.

Not yet recruiting

Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension (RESTART)

Hypertension | Kidney Transplantation
Hippocration General Hospital
ReCor Medical, Inc.

Recruiting

Effect of Renal Denervation on Stress, Hypertension and Anxiety Management (ERSHAM)

Stress | Anxiety | Hypertension Arterial

Greece
University of Leipzig
ReCor Medical, Inc.

Recruiting

Renal Denervation to Treat Heart Failure With Preserved Ejection Fraction (UNLOAD-HFpEF)

Heart Failure With Preserved Ejection Fraction | Hypertension, Renal

Germany
Arecor Limited

Completed

AT278 and NovoRapid® in Glucose Clamp Study

Diabetes Mellitus, Type 1

Austria
Royal Perth Hospital
ReCor Medical, Inc.

Recruiting

REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions. (RESURRECT)

Heart Failure | Chronic Kidney Diseases | End Stage Renal Disease

Australia
Arecor Limited

Completed

AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

Diabetes Mellitus, Type 2

Austria
Arecor Limited

Completed

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Diabetes Mellitus, Type 1

United States
Arecor Limited

Completed

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

Diabetes Mellitus, Type 1

Austria
Cerebos Pacific Limited

Unknown

CMI-168 on Cognitive Function in Healthy Middle-aged Men and Women

Cognitive Change

Taiwan
Aevi Genomic Medicine, LLC, a Cerecor company
Medgenics Medical Israel Ltd.

Terminated

TARGTEPO Treatment for Anemia in PD US Trial

Anemia of End Stage Renal Disease

United States

Clinical Trials Sponsored by Cerecor Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations